IVD & Diagnostics
50 articles
Medicare CLFS Under PAMA: What IVD & Diagnostic Developers Must Know in 2026
Comprehensive 2026 guide to Medicare CLFS lab payment under PAMA: applicable lab rules, 3-year CDLT cycle, ADLT status, gapfilling, and CAA 2026 Section 6226 updates.
Mongolia Diagnostic & IVD Device Register Teardown: 2024 LMMD Reset
A data-driven teardown of Mongolia's diagnostic and IVD register. Analyze the risk-class split, country-of-origin mix, top manufacturers, and 2024 LMMD regulatory reset.
Bangladesh DGDA Registered Medical Devices Teardown: Chinese IVDs & Class C Majority
A data-driven teardown of Bangladesh's Directorate General of Drug Administration (DGDA) registered medical device list, analyzing risk classes, manufacturers, and importers.
Why One FDA/CE Clearance Opens Far Fewer CGM Markets: The Global Class-Divergence Map
A comprehensive cross-market analysis of continuous glucose monitor (CGM) classification, clinical trial requirements, and reimbursement gates across the US, EU, China, Japan, and Canada.
Zambia ZAMRA Medical Device Registry Teardown: Manufacturers & LTRs
A data-driven teardown of Zambia's ZAMRA medical device and IVD registry. Explore risk-class splits, country of origin trends, and LRP channel concentration.
Ecuador ARCSA Medical Device Register Analysis: 326,334 Records
A data-driven teardown of Ecuador's ARCSA medical device registro sanitario: 326,334 listed records, 22,056 registrations, risk classes I-IV, device types, and titular concentration.
El Salvador DNM Medical Device Registry: 21,607 Approvals & Importer Dynamics
An in-depth analysis of El Salvador's medical device registry (DNM/SRS). Understand active vs. cancelled ratios, risk classes, and top local importers.
Ethiopia Medical Device Registry: 5,915 Approvals & Local Dynamics
A comprehensive teardown of the Ethiopian Food and Drug Authority (EFDA) eRIS database. Review manufacturer origins, top local importers, and regulatory steps.
Uzbekistan Medical Device Registry: 6,572 Approvals & Entry Trends
A data-driven analysis of Uzbekistan's Uzpharm State Register. Discover registration volumes, product categories, and leading foreign suppliers.
China NMPA Device Registration: 14,187 Approvals, Import Mix, and Foreign Wins
A data-driven analysis of China's NMPA medical device registry database. Discover approval volumes, import vs. domestic splits, and strategic pathways for foreign device makers.
WHO Medical Device and IVD Prequalification: The Complete Regulatory Guide
A comprehensive guide to the World Health Organization (WHO) prequalification process for medical devices and IVDs, detailing eligibility, step-by-step pathways, and key 2026 procedural updates.
IVD Registration Compared: FDA 809, EU IVDR, China, Brazil & India
Side-by-side legal-text comparison of IVD registration: FDA 21 CFR Part 809, EU IVDR 2017/746, China SAMR Decree 48, Brazil RDC 830/2023, India MDR 2017 — classes, pathways, who reviews.
IVD Calibrator Traceability: ISO 17511, EU IVDR, and JCTLM Guide
Metrological traceability for IVD calibrators and control materials under ISO 17511:2020 and EU IVDR Annex I Section 9.3, covering calibration hierarchies, JCTLM resources, and common pitfalls.
Abbott Libre Duo CE Mark: Dual Glucose-Ketone CGM Strategy (2026)
Abbott Libre Duo CE mark analysis covering the first continuous glucose-ketone sensor, dual-analyte regulatory strategy, CGM competition, FDA pathway, and wearable convergence.
Liquid Biopsy and Multi-Cancer Early Detection (MCED) Tests: FDA, IVDR Regulatory Pathway
Regulatory guide to liquid biopsy and MCED tests, including FDA pathways, Breakthrough designation, companion diagnostics, EU IVDR classification, clinical evidence, and key market players.
Thermo Fisher Microbiology Divestiture to Astorg: $1.1B Deal Analysis
Analysis of Thermo Fisher's $1.1B microbiology divestiture to Astorg, including deal terms, Oxoid and Remel assets, $645M revenue, and diagnostics strategy.
IV-to-Subcutaneous Shift: OBDS Regulatory Strategy Guide (2026)
Analysis of the IV-to-subcutaneous shift in biologics, covering on-body delivery systems, OBDS combination product pathways, human factors, and market drivers.
Abbott-Exact Sciences $21B Deal: Cancer Diagnostics and IVD Strategy
Analysis of Abbott's $21B Exact Sciences acquisition, including Cologuard, Oncotype DX, deal structure, cancer screening IVD strategy, and precision oncology market impact.
EU Reference Laboratories for IVDR Class D IVDs: EURL Guide
Guide to EU Reference Laboratories under IVDR Article 100 for Class D IVDs, including rollout, affected categories, performance verification, batch testing, and manufacturer preparation.
Antibody Clone Lock and Lot-to-Lot Bridging for Immunoassay IVD Kits
How to lock antibody clones, manage lot-to-lot bridging studies, and maintain immunoassay IVD performance across manufacturing campaigns under FDA QMSR, ISO 13485, and EU IVDR.